Saved in:
| Main Authors: | Arbie Sofia P. Merilleno, Mina Tadrous, Inna Ushcatz, Heather J. Zhao, Aaron M. Drucker |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1111/ijd.17543 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
Single‐centre experience with tralokinumab in dupilumab‐experienced and naïve patients with atopic dermatitis
by: Claire Fossati, et al.
Published: (2024)
by: Claire Fossati, et al.
Published: (2024)
Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real‐world comparative study
by: Tiago Torres, et al.
Published: (2025)
by: Tiago Torres, et al.
Published: (2025)
Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO‐ADOC study)
by: Ziad Reguiai, et al.
Published: (2024)
by: Ziad Reguiai, et al.
Published: (2024)
Effectiveness of dupilumab in tralokinumab‐resistant patients with atopic dermatitis: A real‐world experience from two referral centres
by: Gianluca Tavoletti, et al.
Published: (2024)
by: Gianluca Tavoletti, et al.
Published: (2024)
Fears for tears? Targeted therapies for atopic dermatitis and ocular surface health
by: Carolyn Jack, et al.
Published: (2024)
by: Carolyn Jack, et al.
Published: (2024)
Real‐world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis
by: Teppei Hagino, et al.
Published: (2025)
by: Teppei Hagino, et al.
Published: (2025)
Reply to ‘Real‐world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis’
by: Fabrizio Martora, et al.
Published: (2025)
by: Fabrizio Martora, et al.
Published: (2025)
Effectiveness of dupilumab in pediatric patients with a nummular phenotype of atopic dermatitis
by: Eun Jae Kim, et al.
Published: (2024)
by: Eun Jae Kim, et al.
Published: (2024)
Erythema induratum of Bazin during successful treatment of atopic dermatitis with dupilumab
by: ChaoJing Zhou, et al.
Published: (2024)
by: ChaoJing Zhou, et al.
Published: (2024)
Bridging the gap: Treatment of atopic dermatitis with dupilumab during pregnancy
by: Christian Vestergaard, et al.
Published: (2025)
by: Christian Vestergaard, et al.
Published: (2025)
Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients
by: Francisco José Navarro‐Triviño, et al.
Published: (2024)
by: Francisco José Navarro‐Triviño, et al.
Published: (2024)
Drug survival of abrocitinib compared to dupilumab in adult patients with atopic dermatitis
by: Qingjie Hu, et al.
Published: (2024)
by: Qingjie Hu, et al.
Published: (2024)
Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity
by: Joséphine Dupuis, et al.
Published: (2024)
by: Joséphine Dupuis, et al.
Published: (2024)
A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis
by: Elaine C. Siegfried, et al.
Published: (2024)
by: Elaine C. Siegfried, et al.
Published: (2024)
Detecting T‐cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab
by: Hyungdon Kook, et al.
Published: (2024)
by: Hyungdon Kook, et al.
Published: (2024)
Efficacy of abrocitinib and dupilumab in itch‐dominant atopic dermatitis: An analysis of 2 trials
by: Jonathan I. Silverberg, et al.
Published: (2026)
by: Jonathan I. Silverberg, et al.
Published: (2026)
Pregnancy and breastfeeding outcome in patients with atopic dermatitis treated with dupilumab: the clinical experience of three centers
by: Joana Xará, et al.
Published: (2024)
by: Joana Xará, et al.
Published: (2024)
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate‐to‐severe atopic dermatitis: A nationwide retrospective cohort study
by: Gianluca Avallone, et al.
Published: (2024)
by: Gianluca Avallone, et al.
Published: (2024)
Residual facial erythema in atopic dermatitis patients treated with dupilumab stratified by machine learning
by: Koichi Ashizaki, et al.
Published: (2024)
by: Koichi Ashizaki, et al.
Published: (2024)
Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study
by: Miguel A. Lasheras‐Pérez, et al.
Published: (2024)
by: Miguel A. Lasheras‐Pérez, et al.
Published: (2024)
Clinical effectiveness of combined dupilumab and baricitinib in a patient with multi‐drug resistant severe atopic dermatitis
by: Anna Paola Lugli, et al.
Published: (2024)
by: Anna Paola Lugli, et al.
Published: (2024)
Severe atopic dermatitis in an Asian‐Arabic population treated with dupilumab: A retrospective observational study
by: Radi Al Chalabi, et al.
Published: (2024)
by: Radi Al Chalabi, et al.
Published: (2024)
Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real‐world evidence
by: Lian F. van der Gang, et al.
Published: (2025)
by: Lian F. van der Gang, et al.
Published: (2025)
Effectiveness of dupilumab in the treatment of alopecia areata in patients with concurrent atopic dermatitis: a real‐life retrospective study
by: Gianluca Tavoletti, et al.
Published: (2024)
by: Gianluca Tavoletti, et al.
Published: (2024)
Interplay between diabetes mellitus and atopic dermatitis
by: Dongyun Lei, et al.
Published: (2024)
by: Dongyun Lei, et al.
Published: (2024)
Patient and family burden in pediatric atopic dermatitis and its treatment pattern in Japan
by: Atsushi Otsuka, et al.
Published: (2024)
by: Atsushi Otsuka, et al.
Published: (2024)
Comment on ‘Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity’ by Dupuis et al.
by: Luca Potestio, et al.
Published: (2024)
by: Luca Potestio, et al.
Published: (2024)
Five‐year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real‐world study
by: Luigi Gargiulo, et al.
Published: (2025)
by: Luigi Gargiulo, et al.
Published: (2025)
International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study
by: Anouk G. M. Caron, et al.
Published: (2024)
by: Anouk G. M. Caron, et al.
Published: (2024)
What is atopic dermatitis?
Published: (2025)
Published: (2025)
Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world
by: Ayu Watanabe, et al.
Published: (2024)
by: Ayu Watanabe, et al.
Published: (2024)
Long‐term efficacy and safety of dupilumab in adolescents with severe atopic dermatitis: a 3‐year real‐life study
by: Alessandra Chiei‐Gallo, et al.
Published: (2024)
by: Alessandra Chiei‐Gallo, et al.
Published: (2024)
Switching from baricitinib to dupilumab as an advanced‐line treatment in pediatric patients with atopic dermatitis: a retrospective cohort study
by: Ayelet Ollech, et al.
Published: (2024)
by: Ayelet Ollech, et al.
Published: (2024)
The real‐world, long‐term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study
by: Khalaf Kridin, et al.
Published: (2025)
by: Khalaf Kridin, et al.
Published: (2025)
The wide spectrum of disease burden in atopic dermatitis—Implications for more holistic approaches?
by: Alexander Salava
Published: (2024)
by: Alexander Salava
Published: (2024)
Bleach suit for atopic dermatitis
by: Manish K. Shah, et al.
Published: (2024)
by: Manish K. Shah, et al.
Published: (2024)
Disease burden and treatment preference for moderate‐to‐severe atopic dermatitis in Taiwan: A discrete‐choice experiment
by: Yung‐Tsu Cho, et al.
Published: (2025)
by: Yung‐Tsu Cho, et al.
Published: (2025)
Association between atopic dermatitis and prurigo nodularis: a systematic review and meta‐analysis
by: Wei Li, et al.
Published: (2024)
by: Wei Li, et al.
Published: (2024)
Multidisciplinary atopic dermatitis program: A novel approach to managing difficult‐to‐control atopic dermatitis patients
by: Alexis Tracy, et al.
Published: (2024)
by: Alexis Tracy, et al.
Published: (2024)
Nemolizumab‐induced exacerbation of atopic dermatitis
by: Hirofumi Kamada, et al.
Published: (2024)
by: Hirofumi Kamada, et al.
Published: (2024)
Similar Items
-
Single‐centre experience with tralokinumab in dupilumab‐experienced and naïve patients with atopic dermatitis
by: Claire Fossati, et al.
Published: (2024) -
Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real‐world comparative study
by: Tiago Torres, et al.
Published: (2025) -
Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO‐ADOC study)
by: Ziad Reguiai, et al.
Published: (2024) -
Effectiveness of dupilumab in tralokinumab‐resistant patients with atopic dermatitis: A real‐world experience from two referral centres
by: Gianluca Tavoletti, et al.
Published: (2024) -
Fears for tears? Targeted therapies for atopic dermatitis and ocular surface health
by: Carolyn Jack, et al.
Published: (2024)